Smith & Nephew plc · LSE:SN.
Smith & Nephew — AAOS 2019 Investor Event
19 slides from Smith & Nephew's conference presentation, Jul 28, 2019
Slide 1: Smith & Nephew AAOS 2019 Investor Event
Smith & Nephew AAOS 2019 Investor Event
Slide 2: Forward looking statements and non-IFRS measures
Forward looking statements and non-IFRS measures Cautionary Statement Regarding Forward Looking Statements This document contains forward-looking information related to Smith & Nephew, Osiris and the proposed transaction that involves substantial risks and uncertainties that could cause actual resul
Slide 3: Agenda
Agenda Digital surgery and robotic eco-system Namal Nawana, Chief Executive Officer NAVIO™ and robotic surgery Skip Kiil, President of Orthopaedics Osiris Therapeutics Namal Nawana, Chief Executive Officer 3
Slide 4: Vision of a robotic ecosystem
Vision of a robotic ecosystem Augmented reality goggles to enhance surgeon’s precision Next-gen robotic arm with Haptic feedback-enabled intraoperatively surgical navigation capabilities gloves manipulate robotic (e.g., digital tissue arm with high surgical segmentation) precision 4
Slide 5: Moving from robotic-assisted surgery to a digital ecosystem
Moving from robotic-assisted surgery to a digital ecosystem 2019 2020 Future developments NAVIO™ Surgical System BlueBelt acquired by First launch of next- Development incorporating Smith & Nephew in 2016 generation platform stand-alone robotic arms, augmented reality Launch of NAVIO 7.0 in
Slide 6: The future robotic ecosystem in Sports Medicine
The future robotic ecosystem in Sports Medicine Module designed for seamless integration into arthroscopic tower for Sports Medicine and ENT surgery Expansion to Ambulatory Surgery Centre outpatient procedure base 6
Slide 7: NAVIO and robotic surgery
NAVIO and robotic surgery Skip Kiil, President of Orthopaedics 7
Slide 8: NAVIO Surgical System
NAVIO Surgical System Accuracy with only Handheld Unicompartmental knee, Indications handheld technology Robotics Total knee, Patellofemoral joint Simplified process No CT Robotic or MRI Techniques Cut Guide, Distal Bur, Bur All with real-time imaging Unique, intra-operative 3D model Custom Compact
Slide 9: NAVIO 7.0
NAVIO 7.0 Improving efficiency, in process simplification where speed matters in the OR. Improved real-time inter-operative data in the OR with reduction of landmark points from 7 to 2. Improved real-time planning with a single simplified user interface, Reducing inter- operative steps by 40% 9
Slide 10: NAVIO 7.0: Adding to the range of knee applications
NAVIO 7.0: Adding to the range of knee applications LEGION™ JOURNEY™ II ANTHEM™ Total Knee System Active Knee System Total Knee System LEGION w/ LEGION PS VERILAST™ Technology LEGION CR JOURNEY II XR JOURNEY II BCS JOURNEY II CR GENESIS™ II Total Knee System NAVIO 7.0 to bring Robotics- assisted sup
Slide 11: Next generation platform
Next generation platform Reduced footprint console design for simple operating room integration. Flexible configurations to fit into any operating room or multiple clinical specialities Potential for this enabling technology to become the robotics platform of choice for ASCs 11
Slide 12: Next generation platform
Next generation platform More powerful computing capabilities and faster response rate between camera and drill Reduced latency with new handset Larger bur, rotatable tracker and integrated suction 12
Slide 13: Brainlab partnership to create multi-asset robotic ecosystem
Brainlab partnership to create multi-asset robotic ecosystem Purchase of Brainlab’s orthopaedic joint reconstruction business and installed base of >500 accounts, with intangible assets Used in >40,000 Orthopaedic cases each year Hip software from Brainlab to be installed onto NAVIO Exclusiv
Slide 14: Vision of a robotic ecosystem
Vision of a robotic ecosystem Augmented reality goggles to enhance surgeon’s precision Next-gen robotic arm with Haptic feedback-enabled intraoperatively surgical navigation capabilities gloves manipulate robotic (e.g., digital tissue arm with high surgical segmentation) precision 14
Slide 15: Osiris Therapeutics
Osiris Therapeutics Namal Nawana, Chief Executive Officer 15
Slide 16: Adding to recent bolt-on deals
Adding to recent bolt-on deals Acquisition of Rotation Medical, Q4 2017 Acquisition of Ceterix, Q1 2019 $125m initial consideration, plus up to $85m in $50m initial consideration plus up to a further $55m milestone payments over the next five years REGENETEN™: a novel tissue regeneration techn
Slide 17: Osiris: high-growth company delivering regenerative medicine products
Osiris: high-growth company delivering regenerative medicine products & Cryopreserved placental Cryopreserved placental tissue Bone matrix for bone Allograft for articular membrane for acute as wound covering or wrap repair cartilage repair and chronic wounds for soft tissue repair 9M 2018 sales: $7
Slide 18: Osiris deal financials
Osiris deal financials • Purchase price of $19.00 per share in cash, 9 months to 37% premium to 90-day average 30 September 2018 2017 • Total consideration of approximately $660m, $m $m financed from existing cash and debt facilities Revenue 102.0 85.9 • Transaction expected to complete in Q2 2019,
Slide 19: Questions
> smith&nephew Questions 19